ReviewPrecision clinical medicine2025
Glycosylation in kidney diseases.
Review in Precision clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Construction and validation of a glycosylation-related diagnostic model and immune characterization in lupus nephritis.Clinical rheumatology · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- Article
- Spatial proteomics in precision medicine: technologies, bioinformatics, and translational applications.Precision clinical medicine · 2026Review
- Pressure cycling technology-assisted data-independent acquisition proteomics reveals molecular alterations and potential therapeutic targets in minor glomerular abnormalities.Precision clinical medicine · 2026Article
- Regulation of cancer cell adhesion, progression, and epithelial-to-mesenchymal transition by N-glycosylation.Precision clinical medicine · 2026Article
- Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice.Frontiers in immunology · 2026Review
- Engineered Protein Modification: A New Paradigm for Enhancing Biosensing Sensitivity and Diagnostic Accuracy.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein glycosylation is a critical post-translational modification that influences protein folding, localization, stability, and functional interactions by attaching glycans to specific sites. This process is crucial for biological functions of glycoproteins, and aberrant glycosylation can lead to genetic disorders, immune system issues, and multi-organ pathologies. Recent advancements in glycoproteomic technologies have made the study of protein glycosylation a key focus for understanding the pathogenesis of kidney diseases. This review provides a comprehensive overview of protein glycosylation mechanisms, its biological roles, molecular pathways, and significant functions in renal physiology and pathology. It specifically highlights the dynamic changes and regulatory networks associated with aberrant glycosylation in kidney diseases such as immunoglobulin A nephropathy, diabetic kidney disease, autosomal dominant polycystic kidney disease, renal cell carcinoma, and acute kidney injury. It also evaluates the clinical applications of related technologies and biomarkers. Additionally, it discusses the challenges in developing glycosylation-targeted therapeutic strategies. Future research should focus on clarifying cell-specific glycosylation regulatory networks in the kidney, integrating glycobiology with multi-omics approaches, and improving precision diagnostics and treatment for kidney diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.